DBI Magnums Caffeine Tablets Recalled for CGMP Deviations
ULTRAtab Laboratories, Inc. is voluntarily recalling DBI Magnums Tablet (Caffeine 200 mg) due to Current Good Manufacturing Practice (CGMP) deviations. The recall affects approximately 8.7 million tablets distributed to three distributors.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 2/5 (Moderate).
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: This is an FDA Class II recall for CGMP deviations. The source text does not report any illnesses, injuries, or hospitalizations. CGMP deviations are manufacturing process violations that represent a potential for harm but do not indicate an immediate serious health risk without reported adverse events, placing this in the Moderate category per the rubric.
Plain-English summary
ULTRAtab Laboratories, Inc., located in Highland, New York, is voluntarily recalling DBI Magnums Tablet (Caffeine 200 mg) in multiple package configurations, including 100-count and 500-count bottles, 3-count and 36-count packets, and bulk containers (NDC 62959-941-00).
The recall was initiated due to Current Good Manufacturing Practice (CGMP) deviations identified at the manufacturing facility. Approximately 8,727,657 tablets are affected. The bulk product was distributed to three distributors, who may have distributed the finished product further.
Affected product codes are M941L and M940LA, with bulk lot numbers 19C065, 19F081, 19H083, and 17D088. Consumers or health care providers in possession of this product should contact ULTRAtab Laboratories, Inc. for instructions on return or disposal.
The recall was initiated on January 26, 2022, and classified as a Class II recall by the FDA on February 9, 2022. The recall was terminated on January 7, 2025.
The recalled product
- Product
- DBI Magnums Tablet (Caffeine 200 mg) 100 and 500 count & 3 and 36 count packets & Bulk Container, ULTRAtab Laboratories, Inc., Highland, NY NDC 62959-941-00
- Manufacturer
- ULTRAtab Laboratories, Inc.
- Category
- Drug — Caffeine Supplement
- Affected units
- 8,727,657
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (4)
- Product Codes: M941L M940LA Bulk Lots: 19C065
- 19F081
- 19H083
- 17D088
Distribution
Distribution scope not specified by the agency.
Part of a larger recall action
This product is one of 33 recalled by ULTRAtab Laboratories, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 33 products in this recall →Related recalls
Same manufacturer · ULTRAtab Laboratories, Inc.
See all →- ModerateHPC Tablet Drug Recalled Due to CGMP Manufacturing Deviations
FDA (Drugs) · 2022-02-16
- ModerateMelatonin ER supplement recalled for manufacturing practice deviations
FDA (Food) · 2022-02-16
- ModerateDietary supplement melatonin recall due to manufacturing deviations
FDA (Food) · 2022-02-16
- Moderate
- ModerateCaffeine dietary supplement recalled due to manufacturing practice deviations
FDA (Food) · 2022-02-16
Same hazard · cgmp deviation
See all →- ModeratePritam International Recalls Brush Buddies Toothpaste Due to CGMP Deviations
FDA (Drugs) · 2026-10-28
- ModerateARU Toothpaste Recalled for CGMP Deviations
FDA (Drugs) · 2026-10-28
- ModeratePritam International Recalls Brush Buddies Fluoride Toothpaste for CGMP Deviations
FDA (Drugs) · 2026-10-28
- ModeratePritam International Recalls Brush Buddies Toothpaste Due to CGMP Deviations
FDA (Drugs) · 2026-10-28
- ModeratePritam International Recalls My Little Pony Toothpaste for CGMP Deviations
FDA (Drugs) · 2026-10-28
Similar recalls
- ModerateCaffeine dietary supplement recalled due to manufacturing practice deviations
FDA (Food) · 2022-02-16
- ModerateDBI 357 Super Magnum Caffeine Tablets Recalled for cGMP Deviations
FDA (Drugs) · 2022-02-09
- ModerateCaffeine vitamin supplement tablets recalled for manufacturing deviations
FDA (Food) · 2022-02-16
- ModerateCaffeine vitamin supplement recalled for manufacturing process deviations
FDA (Food) · 2022-02-16
- Moderate
- ModerateMelatonin supplement MidNite Tablet recalled for manufacturing deviations
FDA (Food) · 2022-02-16